Open AccessHumoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
Author(s) -
Louise Bouard,
Benoît Tessoulin,
Catherine Thiéblemont,
Kamal Bouabdallah,
Thomas Gastinne,
Lucie Obéric,
Sylvain Carras,
Caroline Delette,
Olivier Casasnovas,
Caroline Dartigeas,
Victoria Cacheux,
Sibylle Masse,
Olivier Hermine,
Steven Le Gouill
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279561
Subject(s) - hypogammaglobulinemia , neutropenia , medicine , autologous stem cell transplantation , mantle cell lymphoma , rituximab , gastroenterology , transplantation , immunology , incidence (geometry) , lymphoma , antibody , chemotherapy , physics , optics
Rituximab maintenance (RM) after autologous stem cell transplantation (ASCT) is standardof-care for young patients with mantle cell lymphoma (MCL). RM may enhance posttransplantation immune-depression and risk of infections. We compared infection incidence and immune consequences of RM versus observation in transplanted MCL patients.All randomized patients included in the LyMa trial were eligible. The following parameters were collected prospectively: occurrence of fever, infection, hospitalization, neutropenia, hypogammaglobulinemia, CD4 lymphopenia and gamma globulin (Ig) substitution. The post-ASCT period was divided into 4 periods in order to assess the possible effects of RM or ASCT on immune status.Each arm included 120 patients. Concerning infection incidence and all biological parameters, there was no difference between the 2 arms during the first year post-ASCT. After this period, RM patients were more exposed to fever (p=0.03), infections (p=0.001), hypogammaglobulinemia (p=0.0001) and Ig substitution (p